Lilly Evaluating Audit Committee Responsibilities In Light Of New NYSE Rules
Executive Summary
Lilly is evaluating the legal and regulatory oversight responsibilities of its audit committee in light of New York Stock Exchange Corporate Governance Rules
You may also be interested in...
Off-Label Promotion Prosecutors Watch Second-Generation Indications
Federal prosecutors weighing action against off-label drug promotions will look carefully at the indications manufacturers seek for second-generation products as a marker for whether to pursue a case, Boston Assistant U.S. Attorney Michael Loucks told an American Conference Institute forum Oct. 21 in New York City
Compliance Officers Make Good “Whistleblowers” – U.S. Prosecutor Sheehan
Corporate compliance officers will make up the next wave of "whistleblowers" in health care fraud cases, Philadelphia Associate U.S. Attorney James Sheehan said at the Food & Drug Law Institute Enforcement & Litigation Conference in Washington, D.C. Sept. 22
Drug Manufacturer Education Grants To Purchasers May Be Kickback, IG Says
Education and research grants to purchasers from pharmaceutical manufacturers may violate the anti-kickback statute, the HHS Inspector General's compliance guide contends